These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12627409)

  • 1. Kullback-Leibler divergence for evaluating bioequivalence.
    Dragalin V; Fedorov V; Patterson S; Jones B
    Stat Med; 2003 Mar; 22(6):913-30. PubMed ID: 12627409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J; Ting N; Wei GC; Burdick RK
    Stat Med; 2002 Jul; 21(13):1825-47. PubMed ID: 12111892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tests for individual and population bioequivalence based on generalized p-values.
    McNally RJ; Iyer H; Mathew T
    Stat Med; 2003 Jan; 22(1):31-53. PubMed ID: 12486750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population and individual bioequivalence: lessons from real data and simulation studies.
    Zariffa NM; Patterson SD
    J Clin Pharmacol; 2001 Aug; 41(8):811-22. PubMed ID: 11504268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case studies, practical issues and observations on population and individual bioequivalence.
    Zariffa NM; Patterson SD; Boyle D; Hyneck M
    Stat Med; 2000 Oct; 19(20):2811-20. PubMed ID: 11033577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescribability and switchability of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    J Control Release; 1999 Nov; 62(1-2):33-40. PubMed ID: 10518632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modified large sample approach in the assessment of population bioequivalence.
    Quiroz J; Ting N; Wei GC; Burdick RK
    J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing individual bioequivalence with high-order cross-over designs: a unified procedure.
    Hsuan FC; Reeve R
    Stat Med; 2003 Sep; 22(18):2847-60. PubMed ID: 12953284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Applying multilevel models in evaluation of bioequivalence (I)].
    Liu QL; Shen ZZ; Chen F; Li XS; Yang M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Dec; 30(12):1302-6. PubMed ID: 20193320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study.
    Dos Reis Serra CH; Mori Koono EE; Kano EK; Schramm SG; Armando YP; Porta V
    Clin Ther; 2008 May; 30(5):902-8. PubMed ID: 18555936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PhRMA perspective on population and individual bioequivalence.
    Barrett JS; Batra V; Chow A; Cook J; Gould AL; Heller AH; Lo MW; Patterson SD; Smith BP; Stritar JA; Vega JM; Zariffa N
    J Clin Pharmacol; 2000 Jun; 40(6):561-70. PubMed ID: 10868305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Types of bioequivalence and related statistical considerations.
    Hauck WW; Anderson S
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A small sample confidence interval approach to assess individual bioequivalence.
    Hyslop T; Hsuan F; Holder DJ
    Stat Med; 2000 Oct; 19(20):2885-97. PubMed ID: 11033583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An alternative single dose parameter to avoid the need for steady-state studies on oral extended-release drug products.
    Paixão P; Gouveia LF; Morais JA
    Eur J Pharm Biopharm; 2012 Feb; 80(2):410-7. PubMed ID: 22108491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The bootstrap in bioequivalence studies.
    Pigeot I; Hauschke D; Shao J
    J Biopharm Stat; 2011 Nov; 21(6):1126-39. PubMed ID: 22023681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multivariate test for population bioequivalence.
    Chervoneva I; Hyslop T; Hauck WW
    Stat Med; 2007 Mar; 26(6):1208-23. PubMed ID: 16810712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An area correction method to reduce intrasubject variability in bioequivalence studies.
    Abdallah HY
    J Pharm Pharm Sci; 1998; 1(2):60-5. PubMed ID: 10945919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.